mirvetuximab soravtansine   Click here for help

GtoPdb Ligand ID: 12250

Synonyms: Elahere® | IMGN-853 | IMGN853 | M9346A-sulfo-SPDB-DM4 | mirvetuximab soravtansine-gynx
Approved drug
mirvetuximab soravtansine is an approved drug (FDA (2022))
Compound class: Antibody
Comment: Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that delivers the cytotoxic maytansinoid DM4 (a microtubule toxin) to cancer cells that express the folate receptor α (FOLR1; P15328) [2]. FOLR1 is an active oncology drug target [8]. Mirvetuximab soravtansine has proven particularly effective against FLOR1 +ve, advanced ovarian tumours [1,4,7].
The chemical structure of DM4 and its sulfo-SPDB linker is represented in PubChem CID 131704480.
Click here for help
Bioactivity Comments
The antibody component (known as M9346A) of mirvetuximab soravtansine binds to FOLR1 with a Kd of 0.08 nM in vitro [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
folate receptor alpha Hs Antibody Binding 10.1 pKd - 1
pKd 10.1 (Kd 8x10-11 M) [1]
Description: Binding affinity of the antibody component of the ADC for hFOLR1